Praxis Precision Medicines Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Praxis Precision Medicines de winst en omzet met respectievelijk 9.9% en 81.1% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 17.7% per jaar.

Belangrijke informatie

9.9%

Groei van de winst

17.7%

Groei van de winst per aandeel

Biotechs winstgroei	28.0%
Inkomstengroei	81.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	12 Nov 2024

Recente toekomstige groei-updates

Recent updates

Praxis Precision Medicines: Great Price Movement, But Still Not Convinced

Oct 13

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Aug 30

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

May 14

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

Mar 26

Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?

Feb 27

We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

May 15

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Jan 27

Praxis Precision Medicines: Genetic Medicines For Neurological Disease

Nov 23

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Oct 14

Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy

Apr 30

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Mar 12

Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares

Jan 18

Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.

Jan 07

Praxis Precision Medicine plummets 27% on clinical hold on lead drug

Nov 10

Winst- en omzetgroeiprognoses

NasdaqGS:PRAX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	32	-256	-130	-117	8
12/31/2025	1	-237	-193	-171	10
12/31/2024	1	-182	-298	-128	10
9/30/2024	2	-151	-100	-99	N/A
6/30/2024	2	-124	-95	-95	N/A
3/31/2024	2	-125	-99	-99	N/A
12/31/2023	2	-123	-111	-111	N/A
9/30/2023	2	-138	-116	-116	N/A
6/30/2023	1	-157	-138	-138	N/A
3/31/2023	1	-183	-164	-164	N/A
12/31/2022	N/A	-214	-185	-185	N/A
9/30/2022	N/A	-231	-202	-201	N/A
6/30/2022	N/A	-232	-182	-180	N/A
3/31/2022	N/A	-208	-154	-153	N/A
12/31/2021	N/A	-167	-126	-125	N/A
9/30/2021	N/A	-135	-100	-100	N/A
6/30/2021	N/A	-111	-90	-90	N/A
3/31/2021	N/A	-88	-70	-70	N/A
12/31/2020	N/A	-70	-53	-53	N/A
9/30/2020	N/A	-53	-42	-42	N/A
6/30/2020	N/A	-44	-36	-36	N/A
3/31/2020	N/A	-41	-34	-34	N/A
12/31/2019	N/A	-41	-34	-33	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PRAX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PRAX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PRAX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van PRAX ( 81.1% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van PRAX ( 81.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PRAX naar verwachting over 3 jaar hoog zal zijn

Praxis Precision Medicines Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 20%

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus revenue estimates increase by 35%, EPS downgraded

Price target increased by 11% to US$154

Price target increased by 10% to US$139

Consensus revenue estimates increase by 28%

Recent updates

Consensus EPS estimates fall by 20%

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Praxis Precision Medicines, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Praxis Precision Medicines: Great Price Movement, But Still Not Convinced

Praxis Precision Medicines Announces Positive Topline Results from the EMBOLD study in SCN2A and 8A Developmental Epilepsies, Highlighting the Disease-Modifying Potential of Relutrigine

We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely

Consensus revenue estimates decrease by 22%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Praxis Precision Medicines, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Consensus revenue estimates increase by 35%, EPS downgraded

Price target increased by 11% to US$154

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Praxis Precision Medicines, Inc. to Report Q1, 2024 Results on May 13, 2024

Praxis Precision Medicines, Inc., Annual General Meeting, Jun 05, 2024

Praxis Precision Medicines, Inc. has completed a Follow-on Equity Offering in the amount of $199.999977 million.

Price target increased by 10% to US$139

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

Consensus revenue estimates increase by 28%

Price target increased by 22% to US$150

Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?

Praxis Precision Medicines, Inc. has completed a Follow-on Equity Offering.

Praxis Precision Medicines, Inc. Provides Update on Advancing Clinical Stage Portfolio

Praxis Precision Medicines, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Praxis Precision Medicines, Inc. Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

Consensus revenue estimates increase by 12%

New major risk - Financial position

New major risk - Revenue and earnings growth

High number of new and inexperienced directors

New major risk - Share price stability

Consensus revenue estimates increase by 168%

Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

New major risk - Revenue and earnings growth

Praxis Precision Medicines, Inc. Announces Further Data from Two Additional Analyses of Essential1 Study for Ulixacaltamide

Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study

New major risk - Shareholder dilution

Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA

Price target decreased by 19% to US$9.75

Price target increased by 38% to US$16.50

Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-In-Class Profile

Insider recently bought US$60k worth of stock

Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Price target increased by 13% to US$11.10

Praxis Precision Medicines, Inc. to Advance Prax-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies

High number of new directors

Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Praxis Precision Medicines, Inc. Shares Updates on Prax-562 Phase 2 and Prax-222 Embrave Clinical Study Clinical Study

Praxis Precision Medicines, Inc. Announces Executive Changes

Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02

Praxis Precision Medicines, Inc. Appoints Jill Desimone as Member of Compensation Committee and the NCG Committee

Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline

Price target decreased to US$26.64

Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder

High number of new directors

Praxis Precision Medicines, Inc. Appoints Jill Desimone to Its Board of Directors

We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients

Praxis Precision Medicines, Inc. to Report Q1, 2022 Results on May 09, 2022

Praxis Precision Medicines, Inc., Annual General Meeting, May 26, 2022

Praxis Precision Medicines, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Praxis Precision Medicines Announces Publication of Preclinical Data Highlighting Differentiated and Potent Antiepileptic Activity of PRAX-562

Praxis Precision Medicines: Genetic Medicines For Neurological Disease

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

CFO & Treasurer recently bought US$76k worth of stock

Insider recently bought US$151k worth of stock

Praxis Precision Medicines, Inc. has completed a Follow-on Equity Offering in the amount of $91.25 million.

Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy